THURSDAY, April 25 - Workshops
Morning Sessions
08:15-09:00
Morning Coffee
Registration (check-in/badge pick-up)
09:00-10:00
Small Molecule Docking 
Protein-Ligand Interaction Analysis / Protein-Ligand Docking / Pharmacophore Modeling / High-throughput Docking / Template-Based Docking
10:00-10:30
Morning Break
10:30-12:00
Fragment-based Design: Scaffold Hopping, Fragment Growing and Bioisosteric Replacements 
Scaffold Replacement / Ligand Growing / Bioisosteric Transformations / Pharmacophore Modeling
12:00-13:00
Workshop Lunch
THURSDAY, April 25 - Scientific Presentations
Afternoon Sessions
12:30-13:30
Registration (check-in/badge pick-up)
13:30-13:35
Opening Remarks: David Thompson, CCG
CHAIR: Bhaumik A. Pandya, Vigil Neuroscience
13:35-14:05
Beyond Ro5 Free Ligand Conformational and Dynamical Determinants of Passive Permeability: Computational and Experimental Synergies
Amber Y.S. Balazs, Director, US Analytical, Structural, and Chromatography (ASC) Team, Early Oncology Chemistry NMR Specialist, AstraZeneca
14:05-14:35
Discovery of Selective and Highly Potent RIPK1 Type III Inhibitors for the Treatment of Neurodegenerative Diseases
Lorena Rico, Senior Scientist, Discovery Chemistry, Merck
14:35-15:05
Discovery of MORF-627, an Orally Bioavailable, Selective avb6 Integrin Antagonist for the Treatment of Fibrotic Disease
Jim Dowling, Senior Director, Medicinal Chemistry, Morphic Therapeutic
15:05-15:35
Modeling Ternary Complexes with Molecular Glues: Making Sense of a Sticky Situation
Michael Drummond, Scientific Applications Manager, Chemical Computing Group
15:35-16:05
Afternoon Break
CHAIR: Tamara Hopkins, Kronos Bio
16:05-16:35
Design and Optimization of Brain Penetrant Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitors
Martin Himmelbauer, Principal Scientist, Medicinal Chemistry, Biogen
16:35-17:05
Selective Small Molecule Activation of PKG1α: Structure and Function
Essam Metwally, Principal Scientist, Merck Research Labs
17:05-17:35
Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9/cyclin T1 for MYC-dependent Cancers
Dave Freeman, Director, Hit Discovery Chemistry, Kronos Bio
17:35-17:40
Closing Remarks: David Thompson, CCG
17:40-18:30
Social Reception